Q-omics provides the consensus-scored RBFADN profile across patient tissues and cancer cell-line models. RBFADN expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBFADN is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, RBFADN RNA expression shows 19,691 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where RBFADN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBFADN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBFADN survival associations across molecular data types. RBFADN RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBFADN RNA expression–survival associations across cancer types. High RBFADN expression shows unfavorable associations in ACC, LIHC, MESO and LUAD, but favorable associations in PAAD and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBFADN RNA expression.
This table summarizes RBFADN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RBFADN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBFADN shows lower tumor expression in KICH, BRCA and THCA and higher tumor expression in LIHC, CHOL and COAD. The KICH box plot shows higher RBFADN RNA expression in normal versus tumor tissue (log2 FC = −0.435, t-test p < 0.001).
This table shows molecular features associated with RBFADN in patient tissues and cancer cell lines. In patient samples, RBFADN shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBFADN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
